Special offersSpecial offers
AntiviralsAntivirals
Famvir Generic Famvir
Famciclovir 250mg
BUY NOWBUY NOW A$3.02 Per pill
Lamprene Generic Lamprene
Clofazimine 50mg
BUY NOWBUY NOW A$2.77 Per pill
Rebetol Generic Rebetol
Ribavirin 200mg
BUY NOWBUY NOW A$7.54 Per pill
Relenza Generic Relenza
Zanamivir 5mg
BUY NOWBUY NOW A$150.90 Per item
Symmetrel Generic Symmetrel
Amantadine 100mg
BUY NOWBUY NOW A$1.12 Per pill
Tamiflu Generic Tamiflu
Oseltamivir 75mg
BUY NOWBUY NOW A$8.05 Per pill
Valtrex Generic Valtrex
Valacyclovir 0.5/1g
BUY NOWBUY NOW A$5.25 Per pill
Zovirax Generic Zovirax
Acyclovir 200/400/800mg
BUY NOWBUY NOW A$0.64 Per pill
Search for pillsSearch for pills

TestimonialsTestimonials
I have used viagra before and tried your generic brand and is the same. Except yours cost a lot less. Am very happy and will buy again From softcock to hardcock in 20 minutes what can be better than that ! - thank you chris
Read more »Read more »
NewsNews
    Broad-Spectrum Antivirals: The Future of HIV Treatment? - TheBody.com
    Broad-Spectrum Antivirals: The Future of HIV Treatment?TheBody
    The Global Antivirals Market Expected To Reach $30 Billion By 2017 - OfficialWire (press release)
    The Global Antivirals Market Expected To Reach $30 Billion By 2017OfficialWire (press release)by Press Office In 2010, the global antivirals market was estimated to be worth $22
    deadly pandemic a matter of when, not if - Sydney Morning Herald
    deadly pandemic a matter of when, not ifSydney Morning HeraldThe drugs that would help are the antivirals, such as Relenza and Tamiflu
    Experts Discuss DAAs for Difficult-To-Treat Hep C Patients - Infectious Disease Special Edition
    Infectious Disease Special EditionExperts Discuss DAAs for Difficult-To-Treat Hep C PatientsInfectious Disease Special Editionby Christina Frangou San Francisco—For several months, it has been one of the most pressing questions among clinicians who treat patients with hepatitis C: How well do the two FDA-approved direct-acting antivirals (DAAs) perform in the patients who
    New Antivirals Show Poor Safety in HCV With Cirrhosis - Medscape
    New Antivirals Show Poor Safety in HCV With CirrhosisMedscapeMay 2, 2012 (Barcelona, Spain) — Two relatively new direct-acting antiviral drugs have poor safety profiles in patients with hepatitis C virus (HCV) and cirrhosis, including a high rate of serious adverse events leading to study discontinuation
Live support Online Chat


Our billing is certified by
Secure shopping certificates